000			06770cam a2200469 i 4500
001			991107524761506196
005			20260128114339.0
008			250221t20252025nyu b 001 0 eng d
010			_a 2024005973
020			_a9780593229866 _q(hardcover)
035			_a(OCoLC)1505528503
035			_a(OCoLC)on1505528503
040			_aLMJ _beng _erda _cLMJ _dFLW _dIG# _dOCLCO _dCCPLG _dOCO _dOJ4 _dIMD _dMJ8 _dIMT _dOCLCO _dWIM _dJRX _dOCLCO _dIUK _dOCLCA _dGO4 _dCLE _dWKM _dCQC _dUNB _dHMS _dOCLCO _dY#4 _dOCLCO _dPAU _dP4Q _dTSC _dOCLCO
041			_aEN
043			_an-us---
050	0	4	_aHD9666.9.J6 _bH37 2025
100			_aHarris, Gardiner, _eauthor. _1https://id.oclc.org/worldcat/entity/E39PCjtrkYfFBV8tKpHY8pd8yb _926686
245	1	0	_aNo more tears _b: the dark secrets of Johnson & Johnson _c/ Gardiner Harris.
246	3	0	_aDark secrets of Johnson & Johnson
250			_aFirst edition.
264		1	_aNew York : _bRandom House _c[2025]
300			_axviii, 444 pages ; _c25 cm
500			_a"Deception corruption death" -- Cover.
504			_aIncludes bibliographical references (pages 357-428) and index.
505	0		_aIntroduction: A quintessentially American company — Part I: Consumer products. Section I: Trust from birth. An emotional bond — Three brothers go to New Brunswick, 1860-1968 — Section II: Johnson's baby powder. Mineral twins — The FDA conducts a survey — Birth of the modern FDA — The power of pressure — A meeting at a Harvard hospital — Secrecy is a top priority — A sacred cow — Section III: Tylenol. An infamous crime, the birth of a myth — Problems with the narrative — Never an adversarial relationship — The cost of doing business — Part II: Prescription drugs. A valley of death in drug discovery — Section IV: Procrit. The first great biotech franchise is born — How giving cash to doctors became good business — J & J's biggest-selling drug — A brave researcher breaks the silence — Miracle-Gro for cancer — Section V: Risperdal. A path of a normal life — A treatment for everything and everyone — Serious red flags — A big target — Ice cream and popcorn parties — A turning point — One of the most alarming warnings — They knew they were a good company — Section VI: Duragesic. An epidemic foretold — Opium blossoms in Tasmania — Less prone to abuse — Evolve the value discussion — Section VII: Ortho Evra birth control patch. The pill and the patch — Part III: Medical devices. The FDA goes looking for a savior — Section VIII: Pinnacle metal-on-metal hip implant. Two terrible dilemmas — God, Nazis, and hip implants — Never stop moving — Section IX: Prolift vaginal mesh. A cure for sag — "Usually minor and well manageable" — Part VI: Vaccination. Section X: COVID. A rare shot a redemption.
520			_a"When reporter Gardiner Harris met a woman at an airport bar whose entire family has been shattered by her nephew's use of the drug Risperdal, one she sold to his doctor as a drug sales rep, he began to wonder how many similar stories are out there. This was in 2004, and since then, Harris has been investigating one of the largest players in Big Pharma, continuously reporting on it despite simultaneous landmark journalistic accomplishments, like exposing the extremely toxic mining conditions ignored by coal companies. For decades, pharmaceutical giant Johnson & Johnson was seen as a paragon of ethical conduct, especially considering the company's child-friendly products like baby powder and tearless shampoo. However, Harris has uncovered reams of evidence of deceitful and dangerous corporate practices that reveal a historic threat to the health of the American public. He covers several disasters: tissue death caused by J & J's touted hip replacements, their coverup of baby powder's linkage to cancer, the teen-directed marketing of the life-altering drug Risperdal, and more. The Hatch-Waxman Bill, which is meant to pave the way for lower-priced generic drugs, passed in 1984, and inadvertently created loopholes in the drug approval process which allowed urgency and profit maximization to take precedence over diligence and patient protection. Johnson & Johnson's subsequent lack of oversight, money-grubbing, and flat out lies have resulted in the death or serious injury of millions of people. To many, the peril of falsified science seems distant, but Harris reveals how a combination of misrepresented data and bribe culture directly impact doctors' decisions -- which are devastatingly revealed to be not at all in the interests of patients."-- _cProvided by publisher.
520			_aNo More Tears is a hard-hitting work of investigative journalism that exposes the darker side of Johnson & Johnson, one of America’s oldest and most trusted healthcare companies. Written by New York Times reporter Gardiner Harris, the book traces decades of corporate misconduct hidden behind the company’s carefully cultivated image as a safe, family-friendly “baby company”. The story begins in 2004, when Harris meets a Johnson & Johnson sales representative by chance at an airport bar. Her account of unethical sales practices and the damage they caused to her own family becomes the catalyst for years of reporting that ultimately lead to this book. Harris documents how the company repeatedly put profits before patients, covering up risks and aggressively marketing dangerous products. He examines scandals involving Johnson’s Baby Powder and its links to cancer, the underestimated dangers of Tylenol, the illegal promotion of antipsychotic drugs, cancer treatments that may have worsened tumour growth, and the role of the fentanyl patch Duragesic in fuelling the opioid crisis. Through detailed reporting and insider testimony, the book reveals a pattern of deception, regulatory pressure, and calculated risk-taking that endangered millions of lives. No More Tears dismantles the comforting public image of Johnson & Johnson and presents a troubling portrait of a healthcare giant whose actions often betrayed the trust placed in it.
610	2	0	_aJohnson & Johnson. _926687
610		0	_aJohnson & Johnson. _926687
650		0	_aPharmaceutical industry _xCorrupt practices United States. _zUnited States.
650		0	_aPharmaceutical industry _xMoral and ethical aspects. _926689
650		0	_aMedical care _xCorrupt practices United States. _zUnited States.
650		0	_aMedical ethics.
650	1	0	_aDrug Industry _xethics _926691
650	1	2	_aDelivery of Health Care _xethics
650	1	0	_aProfessional Misconduct _926692
650	2	0	_aEthics, Medical _926693
650	2	0	_aBusiness ethics _93022
651		0	_aUnited States _922762
655		0	_aInformational works _2lcgft _923310
942			_2lcc
999			_c5311 _d5311